TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06541899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polarys Cryolipolysis
Description: The procedure will take place in a session lasting a maximum of 60 minutes, which may vary depending on the amount of fat in the area and the type of applicator chosen (with or without vacuum). The patient will be comfortably positioned, in a position that facilitates suction/fixation of the applicator. An antifreeze membrane will be applied correctly to the skin, avoiding wrinkles. The marked skin area will be positioned in the center of the membrane. The applicator will be positioned in the treatment area at 90° to the skin and will activate the START.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polarys Cryolipolysis
Description: The procedure will take place in a session lasting a maximum of 60 minutes, which may vary depending on the amount of fat in the area and the type of applicator chosen (with or without vacuum). The patient will be comfortably positioned, in a position that facilitates suction/fixation of the applicator. An antifreeze membrane will be applied correctly to the skin, avoiding wrinkles. The marked skin area will be positioned in the center of the membrane. The applicator will be positioned in the treatment area at 90° to the skin and will activate the START.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polarys Cryolipolysis
Description: The procedure will take place in a session lasting a maximum of 60 minutes, which may vary depending on the amount of fat in the area and the type of applicator chosen (with or without vacuum). The patient will be comfortably positioned, in a position that facilitates suction/fixation of the applicator. An antifreeze membrane will be applied correctly to the skin, avoiding wrinkles. The marked skin area will be positioned in the center of the membrane. The applicator will be positioned in the treatment area at 90° to the skin and will activate the START.
Study: NCT05435872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Artificial intelligence Cloud Platform
Description: The Artificial intelligence Cloud Platform would be used as the auxiliary device for endoscopists during the whole endoscopic examination to help endoscopists complete the quality control, indicate potential lesions, and aid in diagnosis.
Study: NCT06057051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent Infinite
Description: iStent Infinite Trabecular Micro-Bypass System
Study: NCT05970029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication style
Description: The verbal communication between the nurse and the patient at the time of analgesic administration

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Communication style
Description: The verbal communication between the nurse and the patient at the time of analgesic administration
Study: NCT06326372

Intervention type: PROCEDURE
Intervention: control
Description: Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95\<oxygen saturation

Intervention type: PROCEDURE
Intervention: ORi+SpO2
Description: Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98 FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg
Study: NCT06149260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pen Injector
Description: Inject semaglutide subcutaneously once weekly, on the same day each week, at any time of day, in a dose increasing mode: the initial dose of 0.25mg QW (once a week), increased to 0.5mg QW after 4 weeks, and then maintained 0.5mg until the end of treatment in total 24 weeks.
Study: NCT05209893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Application based video home exercise for the knee osteoarthritis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper Based Rehabilitation
Description: Paper instruction based home exercise for the knee osteoarthritis
Study: NCT05940285

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic 99mTc-Tetrofosmin CZT-SPECT
Description: Patients included in the study will undergo subsequently at 1-month after acute coronary syndrome Dynamic 99mTc-Tetrofosmin CZT-SPECT followed by FFR and IMR assessment
Study: NCT05718765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACES intervention
Description: The exercise perception intervention program is divided into three stage, and every four weeks is a stage. The theme of the first stage is to make the patient have the intention to exercise. The theme of the second stage is to provide effective support for the patient, so that the patient can take the initiative to start exercise. The theme of the third stage is to enable patients to keep exercising.~The exercise intervention is a 12-week progressive intradialytic combined cycling exercise which proceed in the first HD 2 hours for safety. Each session consisted of a 5-minute warm-up, cool-down and 30-minute cycling at a Rating of Perceived Exertion (RPE) of 12-14. The machine has two exercise types including aerobic exercise and resistance exercise. Every four weeks is divided into a stage. And the time of aerobic exercise and resistance exercise were personally adjusted per stage to maintain the personalized target RPE.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual care with sham intervention
Description: Patients in the control group received usual care and were advised to do sham exercise such as stretch legs and arms about 15 minutes during the first 2 hemodialysis hours.
Study: NCT05662501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pleioflow-RF
Description: Subjects who are going to undergo scheduled cardiac surgery and are prone to developing renal insufficiency, will receive the Pleioflow-RF device in conjunction with IABP during CPB. Subjects will be followed until 30-days post-intervention.
Study: NCT05895214

Intervention type: PROCEDURE
Intervention: oncological relevance of the mesopancreas
Description: Invasion status Invasion depth in mm Depth of mesopancreas in mm Treitz fascia intact (histopathological examination)

Intervention type: PROCEDURE
Intervention: oncological relevance of the mesopancreas
Description: Invasion status Invasion depth in mm Depth of mesopancreas in mm Treitz fascia intact (histopathological examination)
Study: NCT06146543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress ball
Description: Before the procedure begins, the patient's free hand will be given an elastic ball that is large enough to hold in the palm of the hand and squeeze easily. He/she will be asked to squeeze this ball slowly throughout the process. At the end of the procedure, the ball will be removed from his hand and the patient will be relieved.
Study: NCT04954365

Intervention type: DRUG
Intervention: Rescue Post-Operative Nausea and Vomiting (PONV) treatment according to the standard of care (SOC)
Description: Rescue Post-Operative Nausea and Vomiting (PONV) treatment

Intervention type: DRUG
Intervention: Amisulpride
Description: Rescue Post-Operative Nausea and Vomiting (PONV) treatment with Amisulpride
Study: NCT06542731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4578
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Specified dose on specified days
Study: NCT06004401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonopazan +Amoxicillin
Description: Vonopazan 20mg 2//day+Amoxicillin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole +colloidal pectin bismuth +Amoxicillin +Clarithromycin
Description: Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Amoxicillin 1g 2/day+Clarithromycin 500mg 2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonopazan +Minocycline
Description: Vonopazan 20mg 2/day+Minocycline 100mg 2/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole +colloidal pectin bismuth +Metronidazole +Clarithromycin
Description: Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Metronidazole 0.4g 3/day+Clarithromycin 500mg 2/day
Study: NCT04373057

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharide
Description: GOS will be administered at determined dose levels per protocol once daily from about 30 days before transplant to about 4 weeks after transplant.
Study: NCT05845632

Intervention type: OTHER
Intervention: Treatment
Description: Patients were treated with surgery, radiotherapy or surgery with postoperative radiotherapy.

Intervention type: OTHER
Intervention: Treatment
Description: Patients were treated with surgery, radiotherapy or surgery with postoperative radiotherapy.
Study: NCT02847949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGN002
Description: IGN002 is a monoclonal antibody fusion protein
Study: NCT04373057

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin will be administered at comparable dose level as GOS (in Phase II) once daily from about 30 days before transplant to about 4 weeks after transplant.
Study: NCT05953935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OKTO
Description: Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OKTO
Description: Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OKTO
Description: Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OKTO
Description: Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard clinical procedures
Description: standard clinical procedures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard clinical procedures
Description: standard clinical procedures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard clinical procedures
Description: standard clinical procedures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard clinical procedures
Description: standard clinical procedures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard clinical procedures
Description: standard clinical procedures
Study: NCT05953051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction with bone/PrP-composite
Description: During standard ACL reconstruction, the drilled bone debris is collected in a sterile filtered chamber.~Then the bone debris is mixed with PrP. After fixation of the graft the composite is inserted into the drilled tunnel at the interface between tendon to bone. The intraarticular aperture sites are sealed by use of fibrin that is previously gathered out of the PrP as well.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction (Standard)
Description: Standard ACL reconstruction with Semitendinosus alone or plus gracilis, femoral fixation via extracortical fixation by adjustable loop device, tibial fixation via a bio-interference screw or adjustable device
Study: NCT06250582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality therapy
Description: A virtual reality therapy will be applied for 30 minutes. Patients will be wearing the glasses while lying in bed/chair during their regular dialysis session. Vital signs will be monitored repeatedly. At defined times, patients are asked to answer various questionnaires about their physical and mental health.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality therapy
Description: A virtual reality therapy will be applied for 30 minutes. Patients will be wearing the glasses while lying in bed/chair during their regular dialysis session. Vital signs will be monitored repeatedly. At defined times, patients are asked to answer various questionnaires about their physical and mental health.
Study: NCT05747261

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ANB-004, dose 1
Description: Adeno-associated viral vector carrying the SMN gene single infusion at dose 1. The duration of the infusion is about 60 minutes.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ANB-004, dose 2
Description: Adeno-associated viral vector carrying the SMN gene single infusion at dose 2. The duration of the infusion is about 60 minutes.
Study: NCT05616195

Intervention type: OTHER
Intervention: 3D printed bone prosthesis replacement surgery
Description: To report the postoperative complications and limb function of patients who underwent 3D-printed bone prosthesis replacement in Henan Cancer Hospital.
Study: NCT05747261

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ANB-004, dose 3
Description: Adeno-associated viral vector carrying the SMN gene single infusion at dose 3. The duration of the infusion is about 60 minutes.
Study: NCT04898283

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10,000 MG01 +10,000 T521
Description: Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and cupressaceae (Juniperus oxycedrus), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30,000 MG01 +10,000 T521
Description: Purified allergen extract polymerized with glutaraldehyde, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and cupressaceae (Juniperus oxycedrus), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo subcutaneous
Description: The same solution and presentation as the active treatment, but without active ingredients
Study: NCT04614519

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional group
Description: Insufflation pressure at 12mmHg and conventional instrumentation
Study: NCT04418115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture; based on Tradidtional Chinese Medicine
Description: Acupuncture is a form of treatment that involves inserting very thin needles through a person's skin at specific points on the body, to various depths. Research suggests that it can help relieve pain, and it is used for a wide range of other complaints.
Study: NCT05552092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal temperature monitoring according to the depth
Description: Core temperatures will be measured with a tympanic thermometer as a reference. When the tympanic membrane (TM) temperature is constant after measuring three consecutive times at 10 seconds intervals, the temperature will be assumed as the core body temperature.~Initially, the esophageal stethoscope (ES) will be inserted to a depth of 45 cm from the incisor. After 30 minutes of monitoring, when the changes in the body temperatures stabilized, initial temperatures of the TM and ES thermistor will be assessed.~After 5 minutes, ES will be taken out 2 cm back, and the temperatures of each site will be measured when the temperature change of the ES thermistor stabilized below 0.1°C. Eventually, the depth of ES will be changed from 45 to 27 cm with a 2 cm interval, and the temperature at each position will be measured.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anatomical landmark
Description: For the further evaluation of the optimal insertion depth of GDT, anatomical landmarks such as distance from the cricoid cartilage to the carina (CCD) and distance from the carina to the intervertebral disc between T8 and T9 (CDD) will be measured using an electronic caliper on a preoperative chest X-ray.
Study: NCT06566508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide Intracanal medication
Description: Calcium Hydroxide Intracanal medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leddermix Intracanal medication
Description: Leddermix Intracanal medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asiaticoside Intracanal medication
Description: Asiaticoside Intracanal medication
Study: NCT06417723

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary nerve block
Description: It is aimed to reach the maxillary nerve trace with a peripheral nerve block needle using the suprazigomatic approach and to create a temporary block in the maxillary nerve with local anaesthetic injection.
Study: NCT06526923

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SP-101 and doxorubicin Cohort 1
Description: Single inhaled dose of SP-101 and doxorubicin Dose 1

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SP-101 and doxorubicin Cohort 1
Description: Single inhaled dose of SP-101 and doxorubicin Dose 1

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SP-101 and doxorubicin Cohort 2
Description: Single inhaled dose of SP-101 and doxorubicin Dose 2

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SP-101 and doxorubicin Cohort 2
Description: Single inhaled dose of SP-101 and doxorubicin Dose 2
Study: NCT04594200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback (A&F)
Description: In this protocol, we propose comparing 2 intervention design elements in a multifactorial design. Specifically, we will evaluate:~i) an emphasis on antibiotic-associated harms in comparison to messages that focus on lack of benefit; ii) simple versus adjusted peer comparators to represent a target for the prescribing quality indicators~We will also investigate the effects of the inclusion of materials developed by Choosing Wisely Canada (CWC) - namely the viral prescription pad - to help physicians act upon the feedback to reduce their prescribing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback (A&F)
Description: In this protocol, we propose comparing 2 intervention design elements in a multifactorial design. Specifically, we will evaluate:~i) an emphasis on antibiotic-associated harms in comparison to messages that focus on lack of benefit; ii) simple versus adjusted peer comparators to represent a target for the prescribing quality indicators~We will also investigate the effects of the inclusion of materials developed by Choosing Wisely Canada (CWC) - namely the viral prescription pad - to help physicians act upon the feedback to reduce their prescribing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback (A&F)
Description: In this protocol, we propose comparing 2 intervention design elements in a multifactorial design. Specifically, we will evaluate:~i) an emphasis on antibiotic-associated harms in comparison to messages that focus on lack of benefit; ii) simple versus adjusted peer comparators to represent a target for the prescribing quality indicators~We will also investigate the effects of the inclusion of materials developed by Choosing Wisely Canada (CWC) - namely the viral prescription pad - to help physicians act upon the feedback to reduce their prescribing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback (A&F)
Description: In this protocol, we propose comparing 2 intervention design elements in a multifactorial design. Specifically, we will evaluate:~i) an emphasis on antibiotic-associated harms in comparison to messages that focus on lack of benefit; ii) simple versus adjusted peer comparators to represent a target for the prescribing quality indicators~We will also investigate the effects of the inclusion of materials developed by Choosing Wisely Canada (CWC) - namely the viral prescription pad - to help physicians act upon the feedback to reduce their prescribing
Study: NCT05180526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLETLI
Description: 80 mg was given subcutaneously at week 1, followed by 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (12 doses).
Study: NCT05653921

Intervention type: OTHER
Intervention: In vivo confocal microscopy (IVCM)
Description: In vivo confocal microscopy (IVCM) allows for visualization of the corneal structures at the cellular level, allowing for assessment of corneal nerves. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.

Intervention type: OTHER
Intervention: In vivo confocal microscopy (IVCM)
Description: In vivo confocal microscopy (IVCM) allows for visualization of the corneal structures at the cellular level, allowing for assessment of corneal nerves. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.

Intervention type: OTHER
Intervention: In vivo confocal microscopy (IVCM)
Description: In vivo confocal microscopy (IVCM) allows for visualization of the corneal structures at the cellular level, allowing for assessment of corneal nerves. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.
Study: NCT05454293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One Talk at a Time: Race
Description: This intervention consists of short videos that include didactic modules and social modeling for having conversations with children about race, ethnicity, culture, and discrimination. The total intervention takes approximately 1.5-2 hours to complete online, and parents can move through the videos at their own pace.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One Talk at a Time: General
Description: This intervention consists of short videos that include modules and handouts with tips for parent-child communication strategies for navigating difficult topics, such as dating and current events.
Study: NCT04815603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGE-117
Description: Active Treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05734482

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: for subcutaneous injection only

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: for subcutaneous injection only